NVO
Novo Nordisk A/S
NYSE · Healthcare · Drug Manufacturers - General · DK
$46.60
−1.92%Sep 4, 2026, 05:00 UTC
The foundation that controls Novo Nordisk A/S is building a $62 million quantum chip factory in Copenhagen, Denmark.
Source:Sep 2, 2026, 19:15 UTC
Aspen Pharmacare is pursuing the market for generic semaglutide, having obtained regulatory approval in Canada and awaiting registration in about 20 countries including Brazil and South Africa.
Source:Sep 1, 2026, 08:55 UTC
Novo Nordisk launched its Wegovy oral weight-loss pill in Germany on Tuesday, as announced by a company spokesperson.
Source:Aug 31, 2026, 23:17 UTC
China's 2026 National Essential Medicines List took effect on September 1, adding 116 new drugs including four domestic Class 1 innovative drugs and Novo Nordisk's semaglutide.
Aug 29, 2026, 22:45 UTC
Thousands of individual lawsuits have been filed in the U.S. District Court for the Eastern District of Pennsylvania against Novo Nordisk and Eli Lilly, alleging that they failed to adequately warn patients about gastrointestinal risks (gastroparesis, ileus, intestinal blockage) associated with their diabetes and obesity drugs Ozempic, Wegovy, Mounjaro, and Zepbound.
Source:Aug 28, 2026, 04:00 UTC
Novo Nordisk and Eli Lilly are using court orders and public campaigns to combat counterfeit weight-loss drugs.
Source:Aug 27, 2026, 14:18 UTC
Novo Nordisk shares dropped following a bank downgrade reflecting growth concerns, with the stock having fallen 70% since its June 2024 peak.
Source:Aug 27, 2026, 11:02 UTC
Denmark raised its 2026 economic growth forecast for the fourth time, citing a bigger-than-expected boost from Novo Nordisk's new weight-loss pill.
Source:Aug 27, 2026, 03:19 UTC
Novo Nordisk submitted a marketing application to China's National Medical Products Administration for its oral semaglutide tablet (Novo Weight) for long-term weight management, and the application has been accepted for review.
Aug 25, 2026, 23:59 UTC
The U.S. federal government, through CMS, announced the BALANCE Model allowing state Medicaid programs to join between May 2026 and January 1, 2027, to negotiate discounted prices for weight-loss drugs, but as of mid-August 2026 no participating states have been named.
Source:Aug 25, 2026, 17:00 UTC
Novo Nordisk announced on August 11 that it is rolling out Awiqli, a weekly insulin injection for Type 2 diabetes, the first weekly dose to reach the market after FDA approval in March.
Source:Aug 24, 2026, 17:30 UTC
Roche signed a licensing deal with Hanmi Pharm for HM17321, an obesity drug candidate, paying $190 million upfront with up to $2.3 billion in milestones and royalties, for rights outside South Korea.
Source:Aug 24, 2026, 12:30 UTC
Lexicon Pharmaceuticals earned a $10 million milestone payment from Novo Nordisk after achieving a key Phase 1 development milestone for LX9851, an oral non-incretin obesity candidate being developed by Novo Nordisk.
Source:Aug 20, 2026, 23:59 UTC
Hacker group FulcrumSec leaked 1.2 terabytes of data stolen from Danish pharmaceutical company Novo Nordisk on the open internet on 12 August 2026, following an earlier sample leak on 17 July 2026.
Source:Aug 20, 2026, 11:00 UTC
Celon Pharma announced that its generic semaglutide product Reduzek matched Novo Nordisk's Wegovy and Ozempic in an early-stage bioequivalence study.
Source:Aug 20, 2026, 01:23 UTC
United Laboratories issued a profit warning, expecting net profit of about RMB 340 million for the six months ended June 2026, down about 82% from RMB 1.893 billion a year earlier.
Source:Aug 19, 2026, 07:32 UTC
Novo Nordisk has begun testing a low-dose oral tablet version of Wegovy in a new obesity study.
Aug 12, 2026, 22:53 UTC
Novo Nordisk CEO Mike Doustdar defended the company's lawsuit against Eli Lilly over its weight-loss drug advertising.
Source:Aug 11, 2026, 15:15 UTC
The Delhi High Court directed Sun Pharma to obtain court approval before launching semaglutide tablets, following a patent infringement suit filed by Novo Nordisk.
Source:Aug 10, 2026, 12:38 UTC
Novo Nordisk and Amazon Web Services announced a strategic partnership to accelerate drug discovery using AI and cloud technology, including the creation of a joint innovation center in London.
Aug 7, 2026, 13:55 UTC
Novo Nordisk reported first-half 2026 revenue of 175.311 billion Danish kroner (about $27 billion), up 13% year-over-year.
Source:Aug 7, 2026, 07:55 UTC
Novo Nordisk China released its first sustainability case collection and held a launch event in China on August 6, 2026.
Source:Aug 5, 2026, 13:54 UTC
Novo Nordisk's oral semaglutide Rybelsus 14mg received approval in China for a new indication to reduce cardiovascular event risk in high-risk type 2 diabetes patients.
Source:Aug 5, 2026, 13:43 UTC
Novo Nordisk obtained a Dutch court injunction to protect patients from an unapproved illegal compounded semaglutide nasal spray.
Aug 4, 2026, 13:12 UTC
H1 and Novo Nordisk announced a partnership to scale AI-driven clinical development.
Source:Jul 31, 2026, 17:24 UTC
BioAge Labs Inc. stock plunged on Friday after disappointing Phase 3 cardiovascular trial results from Novo Nordisk A/S raised concerns about NLRP3-targeting therapies.
Source:Jul 31, 2026, 15:15 UTC
Novo Nordisk's market capitalization fell by $30.7 billion to $198.5 billion after a failed heart drug trial, a nearly 69% decline from its June 2024 all-time high of $635.7 billion.
Jul 31, 2026, 11:27 UTC
Novo Nordisk announced that its drug Ziltivekimab failed to reduce the risk of major adverse cardiovascular events (MACE) compared to placebo.
Jul 24, 2026, 08:33 UTC
Novo Nordisk filed a request in court to preliminarily stop Eli Lilly's allegedly misleading GLP-1 advertising campaign during the litigation.
Jul 21, 2026, 16:15 UTC
Novo Nordisk filed a lawsuit against Eli Lilly in U.S. federal court, accusing Lilly of false advertising in weight-loss drug marketing.
Page 1Next →